Investigations on the 4‐Quinolone‐3‐Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid‐2 Receptor Ligands through a Bioisosteric Approach
暂无分享,去创建一个
M. Cascio | D. Bolognini | R. Pertwee | A. Ligresti | F. Corelli | R. Moaddel | A. Tafi | C. Mugnaini | S. Maione | L. Bellucci | S. Nocerino | Valentina Pedani | S. Pasquini | Maria De Chiaro | M. Valoti | F. Guida | L. Luongo | S. Dragoni | A. Rosenberg | Vincenzo Di Marzo
[1] F. Corelli,et al. Regioselective functionalization of quinolin-4(1H)-ones via sequential palladium-catalyzed reactions , 2011 .
[2] M. Frosini,et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. , 2011, Journal of medicinal chemistry.
[3] R. Moaddel,et al. Development and characterization of immobilized cannabinoid receptor (CB1/CB2) open tubular column for on-line screening. , 2011, Analytical biochemistry.
[4] N. Meanwell. Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.
[5] E. Dreassi,et al. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. , 2010, European journal of medicinal chemistry.
[6] Stephen P. H. Alexander,et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.
[7] M. Cascio,et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. , 2010, Journal of medicinal chemistry.
[8] P. Diaz,et al. Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain , 2010, Anesthesia and analgesia.
[9] M. Cascio,et al. The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice , 2010, British journal of pharmacology.
[10] M. Cascio,et al. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. , 2010, Pharmacological research.
[11] B. Kuhn,et al. A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of medicinal chemistry.
[12] Paul F. Smith,et al. Cannabinoids in the treatment of cancer. , 2009, Cancer letters.
[13] R. Dolle,et al. Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands. , 2009, Current pharmaceutical design.
[14] E. Dreassi,et al. Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. , 2009, European journal of medicinal chemistry.
[15] D. Tulshian,et al. Constitutive activity of cannabinoid‐2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242 , 2009, British journal of pharmacology.
[16] H. Hsieh,et al. Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. , 2009, Journal of medicinal chemistry.
[17] M. Bifulco,et al. Endocannabinoid system modulation in cancer biology and therapy. , 2009, Pharmacological research.
[18] S. Zographos,et al. Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case , 2009 .
[19] P. Anand,et al. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain , 2009, Brain Research Reviews.
[20] L. Alcaraz,et al. Antagonists of the P2X(7) receptor. From lead identification to drug development. , 2009, Journal of medicinal chemistry.
[21] R. Pertwee,et al. Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.
[22] A. Idris. Role of cannabinoid receptors in bone disorders: alternatives for treatment. , 2008, Drug news & perspectives.
[23] Vinod Kumar,et al. Unique Versatility of Ionic Liquids as Clean Decarboxylation Catalyst Cum Solvent: A Metal‐ and Quinoline‐Free Paradigm towards Synthesis of Indoles, Styrenes, Stilbenes and Arene Derivatives under Microwave Irradiation in Aqueous Conditions , 2008 .
[24] Chong-Hwan Chang,et al. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. , 2008, Journal of medicinal chemistry.
[25] S. Hitchcock,et al. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists. , 2008, Journal of Medicinal Chemistry.
[26] L. Botta,et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. , 2008, Journal of medicinal chemistry.
[27] C. Tintori,et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. , 2008, Journal of medicinal chemistry.
[28] Christine Chabot,et al. Sterically biased 3,3-sigmatropic rearrangement of chiral allylic azides: application to the total syntheses of alkaloids. , 2008, The Journal of organic chemistry.
[29] M. Camilleri,et al. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects , 2008, Gut.
[30] V. Adhami,et al. Cannabinoids for cancer treatment: progress and promise. , 2008, Cancer research.
[31] F. Mach,et al. Cannabinoid receptors in acute and chronic complications of atherosclerosis , 2008, British journal of pharmacology.
[32] P. Pacher,et al. Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning , 2008, British journal of pharmacology.
[33] A. Hohmann,et al. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.
[34] N. Stella,et al. CB2 receptor‐mediated migration of immune cells: it can go either way , 2008, British journal of pharmacology.
[35] M. Cascio,et al. The 1,2,3-triazole ring as a peptido- and olefinomimetic element: discovery of click vanilloids and cannabinoids. , 2007, Angewandte Chemie.
[36] Manfred Kansy,et al. High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.
[37] R. Pertwee. Cannabinoids and Multiple Sclerosis , 2007, Molecular Neurobiology.
[38] M. García-Arencibia,et al. Cannabinoids and Neuroprotection in Basal Ganglia Disorders , 2007, Molecular Neurobiology.
[39] K. Valenzano,et al. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. , 2007, Current medicinal chemistry.
[40] Kazuo Kitaura,et al. Pair interaction energy decomposition analysis , 2007, J. Comput. Chem..
[41] J. Crow,et al. The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset , 2006, Journal of neurochemistry.
[42] Li Di,et al. Biological assay challenges from compound solubility: strategies for bioassay optimization. , 2006, Drug discovery today.
[43] J. J. Goodwin. Rationale and benefit of using high throughput solubility screens in drug discovery. , 2006, Drug discovery today. Technologies.
[44] A. Fura,et al. Role of pharmacologically active metabolites in drug discovery and development. , 2006, Drug discovery today.
[45] Jay S. Fine,et al. A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.
[46] G. Cruciani,et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.
[47] G. Caliendo,et al. A suitable 1,2,4-oxadiazoles synthesis by microwave irradiation. , 2004, Bioorganic & medicinal chemistry letters.
[48] W. Humphreys,et al. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. , 2004, Journal of medicinal chemistry.
[49] K. Valko,et al. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. , 2004, Journal of chromatography. A.
[50] M. Guzmán,et al. Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.
[51] A. Galetin,et al. Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies , 2003, Drug metabolism reviews.
[52] Z. Tuba,et al. Synthesis of steroidal diacyl hydrazines and their 1,3,4-oxadiazole derivatives , 2002, Steroids.
[53] R. Pertwee,et al. Cannabinoid receptors and their ligands , 2002, European Neuropsychopharmacology.
[54] H. Iwamura,et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.
[55] J. Owen,et al. A Novel and Efficient Synthesis of 2,3-Dichloroquinoline , 2000 .
[56] R. Pertwee,et al. Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.
[57] P. Casellas,et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[58] Robin Taylor,et al. Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles , 1997 .
[59] Gerhard Klebe,et al. Oxygen and Nitrogen in Competitive Situations: Which is the Hydrogen‐Bond Acceptor? , 1996 .
[60] R. F. Westbrook,et al. The formalin test: scoring properties of the first and second phases of the pain response in rats , 1995, Pain.
[61] P. Soubrié,et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.
[62] Mark S. Gordon,et al. General atomic and molecular electronic structure system , 1993, J. Comput. Chem..
[63] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[64] T. Bonner,et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.
[65] D. Dubuisson,et al. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.
[66] K. Morokuma,et al. The origin of hydrogen bonding. An energy decomposition study , 1977 .
[67] Kazuo Kitaura,et al. A new energy decomposition scheme for molecular interactions within the Hartree‐Fock approximation , 1976 .
[68] W. E. Smith. Formylation of aromatic compounds with hexamethylenetetramine and trifluoroacetic acid , 1972 .
[69] R. Pertwee,et al. Pharmacological actions of cannabinoids. , 2005, Handbook of experimental pharmacology.
[70] Guomin Yao,et al. Adamantylchlorocarbene: characterization and rearrangement to chlorohomoadamant-3-ene , 1999 .